XORTX Therapeutics (XRTX)
Develops oral oxypurinol therapies for gout and kidney disease.
Something off on this page? Send us feedback.
Develops proprietary oral oxypurinol formulations and related kidney-disease assets for gout, ADPKD and other hyperuricemia-related diseases. The business is an externally financed, outsourced clinical-development sponsor whose principal value rests on formulation, use and related patent claims rather than ownership of oxypurinol.
Develops proprietary oral oxypurinol formulations and other uric-acid-lowering approaches for gout and kidney disease. Its near-term program, XRx-026, uses the XORLO formulation for people intolerant of allopurinol; XRx-008 targets autosomal dominant polycystic kidney disease. XRx-101 addresses acute kidney injury linked to respiratory-virus infection, while XRx-225 and acquired VB4-P5 add earlier kidney-disease programs.
Operates from Calgary with a small internal team, outsourced manufacturing and clinical research, and U.S.-focused regulatory and market-access plans. It uses prior oxypurinol and allopurinol evidence where permitted, but no candidate has marketing approval or product revenue. Advancing the portfolio depends on financing, contractor execution, clinical results, regulatory agreements, and protection of formulation, use, and related patent claims.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $992.9K · Total debt $0 · Total assets $6.2M · Shareholders' equity $5.5M
- Revenue
- $0
- Operating income
- −$1.7M
- Net income
- −$1.7M
No dividends on record.
| Institutions1 holder · as of Mar 31, 2026 | 0.02% | 9 ADS | |
| Otherremainder | 99.98% | 55.7K ADS |
55.7K ADS (1 ADS = 25 ordinary shares) as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (55.7K in the company's Sep 3, 2026 report, 278.5K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
TD Waterhouse Canada Inc.Institution | 0.02% | 47 ADS | 13Fas of Mar 31, 2026 |
Armistice Capital, LLCStrategic | —9.99% of class, as filed | — | 13D/Gfiled Feb 14, 2023 ↗ |
Lincoln Alternative Strategies LLCStrategic | —9.90% of class, as filed | — | 13Gfiled Oct 27, 2025 ↗ |
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Takeda (ADR)
Established oral febuxostat for chronic gout and urate lowering.
- Amgen
Later-line biologic for uncontrolled gout after oral therapy.
- Novartis (ADR)
Emerging ADPKD candidate farabursen targets kidney decline.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| XORTX Therapeutics | $2.42 | +12.04% | $690.7K | — | — | — | — |
| Takeda (ADR) | $18.73 | +1.55% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 27.5 | 18.9 | 5.6 | +5.8% |